Drug Profile

SAN 2355

Alternative Names: SAN-2355

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Saniona
Class Antiepileptic drugs
Mechanism of Action KCNQ2 potassium channel stimulants; KCNQ3 potassium channel stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

05 Mar 2025 Preclinical trials in Epilepsy in Denmark (unspecified route) prior to March 2025.
03 Mar 2025 Saniona announces intention to file Clinical Trial Application for Epilepsy by year end 2025
03 Mar 2025 Saniona plans clinical trial for Epilepsy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com